BioSpace News Archive

Nexcella Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201.

Amicus Therapeutics today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million senior secured term loan facilitating a refinancing of existing debt and a $30 million strategic investment in Amicus’s common stock.

Cutera, Inc. is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023.

RenovoRx, Inc today announced that CEO, Shaun Bagai, will present at the ROTH MKM Healthcare Opportunities Conference in New York on October 12, 2023.

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today shared the results of an exploratory analysis evaluating the effects of patient characteristics on baseline vaginal/vulvar symptoms during its Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1) study.

Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round.

Shoulder Innovations Inc., a Grand Rapids, Michigan based leader in the shoulder replacement implant market announced that they have hired Mr. Jeff Points as Chief Financial Officer.

AmbioPharm, a worldwide leader in peptide active pharmaceutical ingredient contract development and manufacturing organization services, announced the appointment of industry veteran Brian Gregg as Chief Executive Officer.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced its schedule of events and presentations at EASD 2023, taking place today through October 6 in Hamburg, Germany, and online.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.